Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles
Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia Abdelhamid, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113569-113569
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

The importance of sulfur-containing motifs in drug design and discovery
Muhamad Mustafa, Jean‐Yves Winum
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 5, pp. 501-512
Closed Access | Times Cited: 115
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 63
Roles and inhibitors of FAK in cancer: current advances and future directions
Hui-Hui Hu, Saiqi Wang, Hai-Li Shang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 19
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Xiangqian Li, Xiaowei Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10581-10605
Closed Access | Times Cited: 96
Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
Xianbo Wu, Jie Wang, Qi Liang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113116-113116
Open Access | Times Cited: 35
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 20
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 8
Targeting Focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders
Xiao Wang, Na Li, Yunhe Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116678-116678
Closed Access | Times Cited: 7
Anticancer benzimidazole derivatives as inhibitors of epigenetic targets: a review article
Nardin Wagih, Islam M. Abdel-Rahman, Nawal El‐Koussi, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 966-1010
Open Access
The Development of FAK Inhibitors: A Five-Year Update
Andrea Spallarossa, Bruno Tasso, Eleonora Russo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6381-6381
Open Access | Times Cited: 33
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma
Feihua Chen, Mouchun Gong, Dengcheng Weng, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 1
Open Access | Times Cited: 5
Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma
Fabio Scianò, Francesca Terrana, Camilla Pecoraro, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 3, pp. 271-289
Closed Access | Times Cited: 4
Overview of Class I HDAC Modulators: Inhibitors and Degraders
Ziqian Huang, Limei Zeng, Binbin Cheng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116696-116696
Closed Access | Times Cited: 3
Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative via Modulating Apoptosis, MAPK/ERK and PI3K/AKT Pathways in Human Breast Cancer Cells
Maiiada Nazmy, Dalia H. Abu‐Baih, Mahmoud A. Elrehany, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 8
Open Access | Times Cited: 10
The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo
Jian Song, Xu Liu, Yifan Zhang, et al.
Bioorganic Chemistry (2022) Vol. 131, pp. 106328-106328
Closed Access | Times Cited: 16
Design, synthesis, molecular docking and biological evaluation of 1,2,4-triazole derivatives possessing a hydrazone moiety as anti-breast cancer agents
Michael Tapera, Hüseyin Kekeçmuhammed, Cansu Ümran Tunç, et al.
New Journal of Chemistry (2023) Vol. 47, Iss. 24, pp. 11602-11614
Closed Access | Times Cited: 8
New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors
Hend A. A. Ezelarab, Amer Ali Abd El‐Hafeez, Taha F. S. Ali, et al.
Bioorganic Chemistry (2024) Vol. 145, pp. 107234-107234
Closed Access | Times Cited: 2
FAK inhibitors in cancer, a patent review – an update on progress
Ya‐Xi Ye, Yuyao Cao, Lisheng Xu, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 593-610
Closed Access | Times Cited: 2
Recent Advances in Synthesis and Anticancer Potential of Triazole-Containing Scaffolds
Devidas S. Bhagat, Gurvinder Singh Bumbrah, Pooja A. Chawla, et al.
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 22, Iss. 16, pp. 2852-2875
Closed Access | Times Cited: 14
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
Yuan Jiang Pan, Haodong Hou, Bo Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115879-115879
Closed Access | Times Cited: 6
FAK Inhibitors As Promising Anticancer Targets: Present and Future Directions
Muhamad Mustafa, Amer Ali Abd El‐Hafeez, Dalia A Abdelhafeez, et al.
Future Medicinal Chemistry (2021) Vol. 13, Iss. 18, pp. 1559-1590
Open Access | Times Cited: 15
Pyridine-Based Glycosides Bearing 1,2,4-Triazole and Their 1,3,4-oxadiazole analogues as Potential EGFR and CDK-2 Inhibitors: Design, Synthesis, Antiproliferative Activity and In Silico Studies
Asmaa F. Kassem, Ahmed Younis, Eman S. Nossier, et al.
Journal of Molecular Structure (2024) Vol. 1313, pp. 138741-138741
Closed Access | Times Cited: 1
Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach
Asha Anand, Powsali Ghosh, Ravi Singh, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 9, pp. 4679-4698
Closed Access | Times Cited: 3
Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFRL858R/T790M Mutations
Moamen A. Hassanin, Muhamad Mustafa, Mohammed A. S. Abourehab, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 857-857
Open Access | Times Cited: 5
Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities
Manasa Gangadhar Shetty, Padmini Pai, Bipasa Dey, et al.
DARU Journal of Pharmaceutical Sciences (2024) Vol. 32, Iss. 1, pp. 263-278
Open Access
Page 1 - Next Page

Scroll to top